Promoted Content Promoted Content


Find FDA Investigational New Drug (IND) Submissions for Psychiatry/Psychology in UNITED STATES


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PF614

            Therapeutic Area: Psychiatry/Psychology Product Name: PF614-MPAR

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: NATIONAL INSTITUTE DRUG ABUSE

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 08, 2021


            PF614-MPAR™ is designed as an extended-release oxycodone prodrug with both trypsin-activated abuse protection (TAAP) and overdose protection through multi-pill abuse resistance (MPAR™) technology.